[go: up one dir, main page]

MX384636B - Método para detectar anticuerpos neutralizantes contra la insulina humana recombinante en suero humano. - Google Patents

Método para detectar anticuerpos neutralizantes contra la insulina humana recombinante en suero humano.

Info

Publication number
MX384636B
MX384636B MX2018004322A MX2018004322A MX384636B MX 384636 B MX384636 B MX 384636B MX 2018004322 A MX2018004322 A MX 2018004322A MX 2018004322 A MX2018004322 A MX 2018004322A MX 384636 B MX384636 B MX 384636B
Authority
MX
Mexico
Prior art keywords
neutralizing antibodies
antibodies against
against recombinant
recombinant human
human insulin
Prior art date
Application number
MX2018004322A
Other languages
English (en)
Other versions
MX2018004322A (es
Inventor
Abhishek Kulshrestha
Narendra Chirmule
Pallavi Hajela
Pawan Kalani
Ramakrishnan Melarkode
Ravi Shankar Maurya
Sudeep Sabde
Original Assignee
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd filed Critical Biocon Ltd
Publication of MX2018004322A publication Critical patent/MX2018004322A/es
Publication of MX384636B publication Critical patent/MX384636B/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/62Insulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un método in vitro para detectar la presencia de anticuerpos neutralizantes de insulina humana recombinante (r HI) mediante análisis de una muestra de suero, caracterizado porque comprende las etapas de: (a) pretratar la muestra de suero para disociar un complejo del anticuerpo con insulina, comprendiendo el pre-tratamiento; i. disociación ácida y tratamiento con carbón vegetal; ii. Neutralizar y tratamiento con PEG; y iii. re- suspensión del sedimento. (b) realizar un ensayo basado en células, en donde el ensayo basado en células comprende las etapas de: i. siembre de células que tienen un receptor por rHI; ii. Nutrición de las células por 18 horas a 26 horas en medio en un medio libre de glucosa; iii. poner en contacto una población de células por pozo con rHI y la muestra de suero pretratada; iv. Lisado de las células y preparación de un lisado claro; y v. evaluación del lisado para fosforilación del receptor de insulina y (c) correlacionar la cantidad de fosforilación con un punto de corte flotante, estando a un nivel de respuesta donde una cantidad de fosforilación que es menor que, o igual que al punto de corte florante, indica que la muestra contiene cantidad de un anticuerpo de rHI.
MX2018004322A 2015-10-15 2016-10-15 Método para detectar anticuerpos neutralizantes contra la insulina humana recombinante en suero humano. MX384636B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN5528CH2015 2015-10-15
PCT/IB2016/056191 WO2017064678A1 (en) 2015-10-15 2016-10-15 Method for detecting neutralizing antibodies against recombinant human insulin in human serum

Publications (2)

Publication Number Publication Date
MX2018004322A MX2018004322A (es) 2018-11-09
MX384636B true MX384636B (es) 2025-03-14

Family

ID=58518001

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004322A MX384636B (es) 2015-10-15 2016-10-15 Método para detectar anticuerpos neutralizantes contra la insulina humana recombinante en suero humano.

Country Status (9)

Country Link
US (1) US11340238B2 (es)
EP (1) EP3362793B1 (es)
JP (1) JP6835835B2 (es)
AU (1) AU2016337598B2 (es)
CA (1) CA3000929C (es)
MX (1) MX384636B (es)
MY (1) MY192159A (es)
RU (1) RU2725142C2 (es)
WO (1) WO2017064678A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
US12285480B2 (en) 2020-03-11 2025-04-29 Nantcell, Inc. Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
CN112362649B (zh) * 2020-11-09 2024-07-12 长春金赛药业有限责任公司 一种rhGH中和抗体的检测方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225583A (en) * 1987-08-06 1991-07-26 Merck & Co Inc Process for purifying hepatitis a virions (hav)
WO1995023231A1 (en) 1994-02-28 1995-08-31 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Cell lines for the identification of substances affecting insulin receptor mediated signal transduction
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
JP4197180B2 (ja) * 2005-06-29 2008-12-17 株式会社シバヤギ 検体中の内分泌物質測定方法
EP2176292A1 (en) * 2007-07-27 2010-04-21 Pfizer Limited Antibody purification process by precipitation
CA2885721A1 (en) 2012-07-11 2014-01-16 Biomimetic Therapeutics, Llc Cell-based assay for neutralizing antibodies
SG11201606291VA (en) * 2014-02-11 2016-08-30 Genzyme Corp Assays for detecting the presence or amount of an anti-drug antibody

Also Published As

Publication number Publication date
US20180306814A1 (en) 2018-10-25
EP3362793B1 (en) 2019-08-28
RU2018114524A3 (es) 2020-02-26
MY192159A (en) 2022-08-03
JP6835835B2 (ja) 2021-02-24
JP2018532115A (ja) 2018-11-01
MX2018004322A (es) 2018-11-09
RU2018114524A (ru) 2019-11-15
US11340238B2 (en) 2022-05-24
EP3362793A1 (en) 2018-08-22
EP3362793A4 (en) 2018-08-22
WO2017064678A1 (en) 2017-04-20
AU2016337598B2 (en) 2022-10-13
BR112018007551A2 (pt) 2018-10-23
CA3000929A1 (en) 2017-04-20
CA3000929C (en) 2023-09-19
AU2016337598A1 (en) 2018-04-26
RU2725142C2 (ru) 2020-06-30

Similar Documents

Publication Publication Date Title
BR112016027475A2 (pt) kit, dispositivo e método para a detecção de câncer pancreático
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MX374652B (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco.
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
EP3816303A3 (en) Breast cancer detection kit or device, and method for detecting breast cancer
EP3967769A3 (en) Lung cancer detection kit or device, and detection method
BR112016028944A2 (pt) kit ou dispositivo para a detecção de câncer do trato biliar e método de detecção
EP3971299A3 (en) Colorectal cancer detection kit or device, and detection method
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
EP4495266A3 (en) Esophageal cancer detection kit or device, and detection method
EP4613881A3 (en) Liver cancer detection kit or device, and detection method
SI3138489T1 (sl) Komplet za določanje koncentracije analita
IN2014DN04645A (es)
CA2951016C (en) Prostate cancer detection kit or device, and detection method
MX2017005888A (es) Dispositivos, sistemas y metodos para la deteccion de analitos.
BR112016016737A2 (pt) Peptídeos, dispositivos e métodos para detecção de anticorpos contra anaplasma
MX384636B (es) Método para detectar anticuerpos neutralizantes contra la insulina humana recombinante en suero humano.
MX2019002818A (es) Metodos para detectar anticuerpos neutralizantes anti-leptina.
BR112017023473A2 (pt) método de detecção e quantificação de ácido nucleico e composições
WO2015077342A3 (en) Detection of arginine methylation of egfr for prediction of resistance to therapy
MX2017005310A (es) Metodos basados en proximidad para seleccion de parejas para ligadura.
BR112016015537A2 (pt) métodos e kits para detectar a presença de sequência polinucleotídea da e. histolytica em amostra
AR104413A1 (es) Anticuerpo de igf-1r y su utilización para diagnosticar cáncer
MY185585A (en) Method for determining dimethyl disulphide
HUE052117T2 (hu) Eszközök és eljárások 1 típusú diabetes veszélyének meghatározására szérum protein biomarkerekkel